Wednesday, November 18, 2026

Subscribe

EconomyEdition TogoTogo

Togo creates autonomous medicines regulator

Togo is creating an autonomous national agency to regulate medicines and other health products. In Lomé, the reform aims to improve quality controls, monitor the market and curb counterfeit products.

Facade of an institutional building in Lomé, with staff and boxes of medicines, in a reportage-style scene.

When medicines become a matter of sovereignty

In Lomé, the issue of medicines is no longer just about opening a pharmacy or receiving a batch of products. It now concerns health security, public trust and the Togolese state’s ability to control a market that has become larger, more fragmented and more exposed to substandard or falsified products. The government has chosen to respond to this pressure with a new institutional structure.

This shift is part of a broader movement seen in West Africa and across the continent. ECOWAS, through the West African Health Organization, has for years been leading efforts to harmonise pharmaceutical rules across its 15 member states. At the continental level, the African Medicines Agency is also making progress, with 32 ratifications recorded in May 2026. Togo is therefore moving forward in a regional space where the regulation of health products has become a matter of cooperation, but also of sovereignty.

An autonomous agency to regain control

On Monday 7 September 2026, the Togolese Council of Ministers adopted the decree establishing the National Agency for the Regulation of Medicines and Other Health Products, and setting out its remit, organisation and operations. The text was made public the following day, Tuesday 8 September, through official channels. The new body is expected to oversee the sector and strengthen pharmaceutical inspections, vigilance, quality control and market surveillance.

The government says the reform is a response to the rapid evolution of the Togolese market. The authorities point to a sector marked by a wider range of products and a growing number of players in the supply and distribution chain. This growth creates opportunities. But it also calls for stronger safeguards, in a country where regulatory functions remained constrained by institutional, technical and operational limitations.

The text goes further. It presents the reform as a way to better coordinate the work of different players and create a more favourable environment for domestic pharmaceutical production. In other words, the agency is not only meant to monitor the sector. It is also expected to support an industrial sector that Lomé wants to make more reliable and less dependent on import chains.

What the Togolese case reveals

This decision did not come out of nowhere. In its performance documents, Togo’s health ministry had already referred to an institutional shift towards a Togolese pharmaceutical regulatory authority, with a stated basis in regional Directive No. 06-2020 of 28 September 2020. In short, the idea of strengthening the regulatory apparatus was already in the pipeline before the September 2026 decree.

The health context lends weight to this change. The World Health Organization says that more than one in ten medicines in low- and middle-income countries are estimated to be substandard or falsified, and that these products undermine patients, families and health systems. The stakes are therefore not abstract. They concern the effectiveness of treatments, confidence in healthcare and public spending.

In Togo, as elsewhere, the issue also arises in informal channels. Products move quickly, sometimes faster than inspections can keep up. The illicit market thrives where regulation lacks resources, a presence on the ground or coordination between health police, customs, inspectors and health professionals. The creation of an autonomous agency addresses this specific weakness. It is an attempt to centralise alerts, inspections and responses.

A regional signal, not just a national one

Togo is part of a broader trend. In West Africa, WAHO has for several years been working to harmonise medicines registration procedures and quality controls, with support from ECOWAS and WAEMU. The aim is simple: to prevent a product from moving from one market to another without comparable standards. In a highly mobile regional space, national regulation alone is no longer enough.

At the continental level, the African Medicines Agency is intended to address part of this coordination gap. The partnership launched in May 2026 between the WHO and AMA aims to strengthen regulatory harmonisation, convergence of standards and access to quality-assured health products. The Togolese reform fits into this approach: it prepares the country to engage more effectively with continental frameworks rather than remain on the sidelines.

For manufacturers, the expected impact is twofold. On the one hand, clearer regulation can reduce grey areas and benefit compliant operators. On the other, it may initially lengthen some procedures while robust inspection and pharmacovigilance mechanisms are built. For households, however, the intended benefit is immediate: safer medicines, more transparent supply chains and fewer risks at the point of purchase.

The reform also says something about Togo’s trajectory. Lomé is seeking to combine public health, regulatory sovereignty and industrial development. In a West African environment where borders are porous to both goods and counterfeit products, the ability to monitor a pharmaceutical market has become a marker of state capacity. The next stage will depend on implementation: funding, recruitment, laboratories, inspections and coordination with ECOWAS and African Union mechanisms.

Automatic translation. Original French version

The quiz

The African economy in six questions

6 questions